Table 3

Patient and irAE outcomes according to bDMARD/tsDMARD type

bDMARD/ tsDMARDType of cancerType of irAEDMARD duration (median, weeks)Association with ICISafetyEfficacyCancer outcomes
Anti-IL-6RLung (n=6)
Melanoma (n=6)
Renal (n=1)
RA-like (n=10)17 (6 ongoing)Yes (n=3)0Partial improvement (n=3)Progression (n=2)
Stable (n=1)
PMR-like (n=2)No (10)Small intestine perforation (n=1)
Septic shock (n=1) (ongoing chemotherapy)
Resolution (n=3)
Partial improvement (n=5)
No efficacy (n=2)
Progression (n=4)
Stable (n=2)
Partial response (n=1)
Remission (n=3)
PsA-like (n=1)
TNF inhibitorsLung (n=4)
Lymphoma (n=1)
RA-like (n=5)8 (2 ongoing)Yes (n=3)Diverticulitis (n=1)
Pneumonitis (n=1)
Resolution (n=1)
Partial improvement (n=1)
No efficacy (n=1)
Progression (n=3)
No (n=2)0Resolution (n=2)Remission (n=2)
AnakinraMelanomaRA-like (n=1)1Yes0No efficacyStable
BaricitinibLungRA-like (n=1)78 (ongoing)No0ResolutionProgression
UstekinumabLungPsA-like (n=1)60 (ongoing)Yes0Partial improvementStable
  • bDMARD, biologic disease-modifying antirheumatic drug; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.